Business Development

Seeking Partners in Innovation

The Business Development & Strategy group works to commercialize intellectual property generated by Fred Hutch researchers so our discoveries and innovations can contribute to better cancer care at the clinic level. We seek industry partners who share our drive to innovate, collaborate and accelerate development of new inventions and approaches. We also cultivate partnerships with philanthropic supporters, research colleagues and policymakers to extend the reach of our scientific advances.

Our areas of focus include:

  • Blood stem cell transplantation and immunotherapy
  • Cancer risk factors and causes, prevention and treatment outcomes
  • Vaccine development and virus-associated cancers
  • Molecular underpinnings of cancer
  • Tumor-specific translational research
Featured technology

Universal Gene Delivery Platform for Targeting of Hematopoietic Stem Cells

Our scientists have developed a novel technique that delivers engineered genes into blood stem cells by using nontoxic gold nanoparticles as couriers.

Recent Startup Successes

All spinouts & startups
Adaptive Biotechnologies

Adaptive Biotechnologies

Juno Therapeutics

Juno Therapeutics

Faraday Pharmaceuticals

Faraday Pharmaceuticals

Adaptive Biotechnologies

Founded in 2009 by two young Fred Hutch researchers — computational biologist Harlan Robins and molecular biologist and geneticist Chris Carlson — Adaptive Biotechnologies has quickly become a leader in high-throughput DNA sequencing of immune system T cells and B cells for research and diagnostic purposes. In 2018, Adaptive announced a partnership with Microsoft Research to combine its sequencing technology with machine learning and artificial intelligence, with the goal of mapping the entire human immune system and eventually developing a universal blood test to detect any diseases a person’s body may be fighting.

Adaptive Biotechnologies

Adaptive Biotechnologies

Adaptive Biotechnologies

Founded in 2009 by two young Fred Hutch researchers — computational biologist Harlan Robins and molecular biologist and geneticist Chris Carlson — Adaptive Biotechnologies has quickly become a leader in high-throughput DNA sequencing of immune system T cells and B cells for research and diagnostic purposes. In 2018, Adaptive announced a partnership with Microsoft Research to combine its sequencing technology with machine learning and artificial intelligence, with the goal of mapping the entire human immune system and eventually developing a universal blood test to detect any diseases a person’s body may be fighting.

Juno Therapeutics

Juno Therapeutics

Juno Therapeutics

Juno Therapeutics was founded in 2013 as a collaboration between Fred Hutch, Memorial Sloan-Kettering Cancer Research Center and Seattle Children’s Research Institute, combining cutting-edge immunotherapy expertise from all three institutions. With $120 million in Series A private investment funding, Juno was one of the largest biotech launches in history. Now a Celgene company, Juno focuses on developing innovative T-cell therapies to treat a broad range of cancers, with the goal of less long-term toxicity than current chemotherapy treatments and the potential to cure even patients with widespread disease.

Faraday Pharmaceuticals

Faraday Pharmaceuticals

Faraday Pharmaceuticals

Founded in 2014, Faraday Pharmaceuticals is advancing pioneering research from Mark Roth’s lab at Fred Hutch on how salts can temporarily shift a person’s metabolism to protect against injury when blood rushes back to a damaged area after circulation has stopped — such as after a heart attack. Roth, a 2007 MacArthur Foundation “genius” grant recipient, has served as president of the company and a member of the board of directors since its founding.

Featured Partnership

LAB591

This collaboration between Fred Hutch and two European partners — Hamburg-based drug discovery and development company Evotec SE and London-based venture capital firm Arix Bioscience — aims to speed up the development of new cancer and infectious disease drugs by providing funding and expertise for the formation of new companies based on discoveries made at Fred Hutch and elsewhere. Launched in 2018, the partnership is administered by the three partner institutions, and all projects are selected by a joint steering committee.

Upcoming Partnering Events & Conferences

All business development events
Sep 10
Sep 10

CAR-TCR Summit Boston (2019)

This is a multi-day event, please click for details
The CAR-TCR Summit celebrates five years of bringing together the world’s leaders in innovating, developing and delivering CAR and TCR based immunotherapies to patients globally with a mission to engineer a cancer-free world.
Location Boston, MA
Host CAR-TCR Summit
Oct 2
Oct 2

Cell & Gene Meeting on the Mesa (2019)

This is a multi-day event, please click for details
The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.
Location Carlsbad, CA
Host Alliance for Regenerative Medicine

Careers in Business Development

Mailing Address

Fred Hutchinson Cancer Research Center
Business Development & Strategy
Mail Stop J2-110
PO Box 19024
Seattle, WA 98109-1024

Material transfer agreements or confidential disclosure agreements: MTA@fredhutch.org

Location & Parking

823 Yale Ave. N.
Seattle, WA 98109

Visitors can park in the visitor parking lot adjacent to the Yale Building.

Campus map

Last Modified, July 09, 2019